Flow Neuroscience

Erik Rehn demonstrates how Flow can reduce depression symptoms with the help of brain stimulation and behavioural therapy.

Flow Neuroscience is a start-up offering a digital, non-medication-assisted therapy for the treatment of clinical depression. It uses a combination of brain stimulation delivered through a headset and therapy delivered by a behavioural intervention app. This enables patients to treat their depression under guidance at home or with the help of a professional. SwissHealth Ventures invested in this start-up in 2021 as co-lead investor in the series A round, along with Khosla Ventures and Zühlke Ventures. The additional capital raised will enable Flow Neuroscience to tailor the existing solution more specifically to the individual patient, expand on its offering designed for use in interventions supervised by a professional, and access new markets.

The Flow Neuroscience solution aims to personalise the treatment of people with mental health problems. SwissHealth Ventures is convinced that this innovative form of therapy will close a gap in the healthcare market.